Skip to main content
. Author manuscript; available in PMC: 2024 May 16.
Published in final edited form as: N Engl J Med. 2023 Oct 21;389(20):1839–1850. doi: 10.1056/NEJMoa2309457

Figure 1. Progression-Free Survival Assessed by Blinded Independent Central Review.

Figure 1.

Panel A shows Kaplan–Meier estimates of progression-free survival assessed by blinded independent central review in the intention-to-treat–pembrolizumab population (i.e., patients whose physicians had planned to treat them with pembrolizumab in the event that they were assigned to the control group). Panel B shows Kaplan–Meier estimates of progression-free survival assessed by blinded independent central review in overall intention-to-treat population. Tick marks on the survival curves indicate censoring of data.